Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KENDO: CDK4/6 Inhibitor vs Chemotherapy in HR+/HER2- Advanced Breast Cancer
NCT03227328Phase 2Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Aug 2017
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib, ribociclib, abemaciclib in Hormone-Receptor-Positive Breast Cancer, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Aug 2017; status: completed.
02
Drugs
palbociclibribociclibabemaciclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT03227328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03227328.